Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + methylprednisolone
- Development stage
- Unknown
- Lead developer
- Baxter
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of cyclophosphamide, an alkylating agent, and methylprednisolone, a corticosteroid. This combination is primarily used for treating lupus nephritis and other autoimmune conditions. The therapy works through cyclophosphamide's DNA-damaging effects on rapidly dividing cells and immune system suppression, combined with methylprednisolone's anti-inflammatory and immunosuppressive properties. Clinical trials have shown that this combination may be more effective than either drug alone for certain conditions, particularly in achieving quicker time to renal response in lupus nephritis.
02
Targets
DNAGR (Glucocorticoid receptor)
Beyond the preview
Go deeper on cyclophosphamide + methylprednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + methylprednisolone.